Ralvenius et al
My Protocol: 0.3 mg BPC-157 injected subcutaneously about 2 inches from my lateral epicondyle, once each morning, for 6 weeks straight
Knowing your full health picture helps us personalize your treatment safely
Mitochondrial dysfunction within atrial myocytes plays a crucial role in driving electrical and structural remodeling processes
The maintenance frequency approach represents hybrid strategy where initial intensive treatment (daily application for 3-6 months) establishes improvements, then reduces to maintenance schedule (2-3 times weekly or every other day) rather than complete discontinuation
These changes are unlikely to be clinically significant as all subjects had etravirine concentrations well above the median protein binding adjusted EC50 of 4 ng/mL (concentration to inhibit 50% of viral replication in vitro).15 Moreover, the reductions in etravirine concentration are comparable to those seen in clinical trials when etravirine was coadministered with darunavir/ritonavir.16 High rates of efficacy were described when etravirine 200 mg twice daily and darunavir/ritonavir were coadministered in patients with extensive resistance, despite a 30% decrease in etravirine pharmacokinetic parameters (compared with historical controls).17 In recent large randomized trials, twice-daily etravirine resulted in additional antiviral effect versus placebo despite the concomitant administration of a boosted protease inhibitor.18,19 Furthermore, in a pooled analysis of these trials, no association between etravirine pharmacokinetics and 48-week efficacy (viral load 90%
